

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.

This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred within the United States absent registration or an exemption from registration requirement. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to register any part of the offering in the United States.



Boan Biotech
博安生物

Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6955)

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) dated 4 June 2025 (the “**Announcement**”) in relation to the placing of new shares in the Company. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

The Company announces that completion of the Placing took place on 11 June 2025.

A total of 38,400,000 new Shares, representing approximately 6.69% of the total issued Shares (as enlarged by the allotment and issue of the Placing Shares), have been placed at the Placing Price of HK\$10.42 per Placing Share to no less than six Placees. To the best of the knowledge, information and belief of the Directors, the Placees are third parties independent of and not connected with the Company, any Director, chief executive or substantial shareholder of the Company, or any of its subsidiaries, or any of their respective associates, and none of the Placees has become a substantial shareholder (as defined under the Listing Rules) of the Company as a result of the Placing.

USE OF PROCEEDS

The Company has received total net proceeds from the Placing (after deducting all relevant fees, costs and expenses borne or incurred by the Company) of approximately HK\$395.60 million. As disclosed in the Announcement, the Company intends to apply the net proceeds from the Placing as follows:

- (a) approximately 50% will be used for research and development of innovative product candidates, including: (i) the clinical trial of BA1106 (CD25 antibody), BA1301 (Claudin18.2 ADC) and BA1302 (CD228 ADC); (ii) non-clinical studies and clinical trial of BA1304 (EGFR/B7H3 bispecific ADC) and PR201 (PD-1/IL-2 probody); and (iii) proof of concept of other innovative product candidates with market potential;
- (b) approximately 20% will be used for the commercialization of marketed and upcoming products; and
- (c) approximately 30% will be used to replenish the Company's working capital and for general corporate purposes.

EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The following table summarises the shareholding structures of the Company (a) immediately before completion of the Placing; and (b) immediately after completion of the Placing:

	Immediately before completion of the Placing		Immediately after completion of the Placing	
	<i>No. of Shares</i>	<i>Approximate %</i>	<i>No. of Shares</i>	<i>Approximate %</i>
Shandong Luye ⁽¹⁾	360,596,456	67.28	360,596,456	62.79
Other existing Shareholders	175,337,238	32.72	175,337,238	30.53
Placees	—	—	38,400,000	6.69
Total	535,933,694	100	574,333,694	100

Notes:

- (1) Shandong Luye is wholly-owned by Luye Pharma.
- (2) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places. Percentages may not add up to 100% due to rounding.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua

Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 11 June 2025

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua, Dr. Dou Changlin and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.